NCT04468425View on ClinicalTrials.gov

Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions
Healthy Subjects
Interventions
DRUG

Tofacitinib Citrate

Period 1: Xelijanz® 5 mg tablet (tofacitinib citrate) for single oral dosing. Period 2: Tofacitinib Citrate Topical Gel 3.2% for repeat topical dosing BID for 14 days.

Trial Locations (1)

Unknown

Syneos Health Facility, Québec

All Listed Sponsors
lead

TWi Biotechnology, Inc.

INDUSTRY

NCT04468425 - Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study | Biotech Hunter | Biotech Hunter